A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes Patients

In brief

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.

Key facts

Study ID

NCT01298518

Run by

Pfizer

People needed

48

Starts

2011-02-01

Expected to finish

2011-05-01

Last updated by the study team

2012-11-06

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and/or female subjects between the ages of 18 and 60 years;
• Body Mass Index (BMI) of >25.0 kg/m2 and <40 kg/m2;
• Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines;
• Subjects who have been on well-tolerated and stable doses of metformin

You may not qualify if…

• Recent evidence (6 months prior to screening) or history of unstable major organ disease;
• Diagnosis of Type 1 diabetes mellitus;
• Current medical history of myocardial infarction, unstable angina, or history of stroke (including TIA) within 6 months prior to Screening;
• Treatment with thiazolidinediones (TZDs), or subcutaneously administered antidiabetic agents;

Where it is running

• Pfizer Investigational Site — Chula Vista, California, United States
• Pfizer Investigational Site — DeLand, Florida, United States
• Pfizer Investigational Site — Miami Gardens, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.